Related Experiment Video
Updated: Aug 8, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Novel approaches to targeting gliomas at the leading/cutting edge
Alexander J Schupper1, Constantinos G Hadjipanayis2
11Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York; and.
Abstract:
Despite decades of clinical trials and surgical advances, the most common high-grade glioma, glioblastoma (GBM), remains an incurable disease with a dismal prognosis. Because of its infiltrative nature, GBM almost always recurs at the margin, or leading edge, where tumor cells invade the surrounding brain parenchyma. This region of GBMs is unique, or heterogeneous, with its own microenvironment that is different from the tumor bulk or core. The GBM microenvironment at the margin contains immunosuppressive constituents as well as invasive and therapy-resistant tumor cells that are difficult to treat. In addition, the blood-brain barrier remains essentially intact at the infiltrative margin of tumors; further limiting the effectiveness of therapies. The invasive margin creates the greatest challenge for neurosurgeons when managing these tumors. The current paradigm of resection of GBM tumors mainly focuses on resection of the contrast-enhancing component of tumors, while GBMs extend well beyond the contrast enhancement. The infiltrative margin represents a unique challenge and opportunity for solutions that may overcome current limitations in tumor treatments. In this review of the current literature, the authors discuss the current and developing advances focused on the detection and treatment of GBM at the infiltrative margin and how this could impact patient outcomes.
Insights
Glioblastoma (GBM) often recurs at its invasive margin due to a unique microenvironment. Targeting this leading edge offers new hope for treating this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Surgical Oncology
Background:
- Glioblastoma (GBM) is a high-grade glioma with a poor prognosis, frequently recurring despite treatment.
- Recurrence is common at the infiltrative margin, a unique microenvironment distinct from the tumor core.
- This margin harbors immunosuppressive cells, therapy-resistant tumor cells, and an intact blood-brain barrier, complicating treatment.
Purpose of the Study:
- To review current and emerging strategies for detecting and treating GBM at its infiltrative margin.
- To explore how addressing the infiltrative margin can improve patient outcomes for glioblastoma.
Main Methods:
- Comprehensive review of existing literature on GBM infiltrative margin detection and treatment.
- Analysis of challenges posed by the GBM microenvironment at the leading edge.
- Evaluation of novel therapeutic approaches targeting tumor invasion and resistance.
Main Results:
- The infiltrative margin presents unique challenges due to its distinct microenvironment and intact blood-brain barrier.
- Current surgical paradigms focusing on contrast-enhancing regions often miss the extent of tumor infiltration.
- Emerging therapies aim to overcome these limitations by targeting the invasive cell population.
Conclusions:
- The GBM infiltrative margin is a critical area for therapeutic intervention.
- Developing targeted strategies for the leading edge is essential for improving glioblastoma treatment efficacy.
- Future research should focus on innovative detection and treatment modalities for the invasive margin to enhance patient survival.
